ImetelChat

This is an interesting video about venetoclax. The onco-community seems to be excited about this drug:

http://www.onclive.com/peer-exchange/am ... lax-in-aml

I guess she didn't respond...?

biotech_bs, you are correct: it is this extended ET study that concluded the following: 'In the ET imetelstat cohort, driver mutation burden at baseline and best reduction during treatment correlate significantly with baseline telomere length.' and: 'We demonstrate higher TLV after 9-10 months of th...

Why didn't you sent it?

I have read various reports from trials that say that imet does inhibit telomerase. I recall a studies that saw actually telomere shortening. If it is the MoA is a different question.

Abstract for ASCO2017, April 3, 2017, 8:00 - 12:00 PM Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor venetoclax enhances apoptosis in vitro and increases survival in vivo in acute myeloid leukemia Abstract is fully by Jansen, but still embargoed. I will eat my shoes if this ...

bio, a totally agree with you. I don't see any reason why the explanation that Anna just gave, wasn't communicated to shareholders in an earlier stage. There must have been a moment in time (when could that have been? Mid 2016?) that it was decided to wait with the trial in order to include more mat...

It is also good to read that we will be informed when plans are definitive, so not only when the trails actually start.

I guess you were right, biotech. I think that Anna gave a valid explanation.

Many of us wondered why the AML trial didn't start end 2016, as was being announced earlier. It is even part of the collaboration agreement. In the meanwhile we know that there will be no new trials before the review end Q2 this year. However, we didn't know why the AML trial also has to wait. So I ...

For those who are interested in becoming member of this board, please send me an email. The address is on the imetelstat.info website. You can also contact me through SeekingAlpha, once you are logged in there. All posts and comments are visible for non-members too. Only if you are interested to act...

Dr.S. said that data of the 'full imetelstat program' were to be submitted to a regulatory body. The question is what is included in this program according to JnJ? Also recall that JnJ is sponsoring numerous research studies on imetelstat and that there is quite a large source of information from ol...

Full text of the Genomeweb article: Jan 30, 2017 | staff reporter NEW YORK (GenomeWeb) – Cancer cells use a variety of mechanisms to survive cellular crisis, including through telomere maintenance processes. By activating telomerase, cancer cells can counteract telomere shortening, and therefore avo...

New report + associated article: Systematic analysis of telomere length and somatic alterations in 31 cancer types link: http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.3781.html#author-information Telomere Length Linked to Genomic Alterations in 31 Cancers https://www.genomeweb.com/cancer/te...

Actually, I don't know what Dr.T. thinks about PRM151. I can't remember him saying something explicit about that. Would be interesting to find out. I do know what his colleague at Mayo, Rubin Mesa, said about it. And off course Srdan Verstovsek is positive about PRM151 too. He is the one who started...

Hi, Hunt. PRM151 is 'one of the two most exciting new drugs' according to Ruben Mesa. The other one is imetelstat. PRM151 is 'dissolving' fibrosis. It is a human made biological substance, that travels around your body to clean up scar tissue and fibrotic tissue. Promedior has found out how to make ...

Thanks, bio. I uploaded it to imetelstat.info. Have you seen this report from 2012: Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks X. Wu et al. (2012) Telomerase is mainly active in human tumor cells, which provides an opportunity f...

Very interesting observation, biotech!

Thanks, Sargasso, for looking up this important remark. I remember that he said that JnJ was going to present the data of the full imetelstat program. That could mean all they know about imetelstat from IMbark, IMerge, Mayo trial and whatever they learned from the numerous pre-clinical studies they ...

Hi Bio, thanks for noting. Good to keep a close eye on it.